Hepatosplenomegaly

Combined enlargement of liver and spleen, reflecting a shared pathological process affecting both organs rather than a diagnosis in itself.

Broad categories of cause include chronic liver disease with portal hypertension (splenomegaly here is congestive, secondary to the liver process), hematological malignancy (leukemia, lymphoma, myeloproliferative disorders, all covered in separate entries), infection (malaria, visceral leishmaniasis, infectious mononucleosis, tuberculosis, brucellosis, schistosomiasis), infiltrative and storage disease (amyloidosis, sarcoidosis, Gaucher disease), and hemolytic anemias (extramedullary hematopoiesis and increased reticuloendothelial workload enlarging both organs).

Left upper quadrant fullness or discomfort (splenic enlargement), right upper quadrant discomfort (hepatic enlargement), early satiety from splenic mass effect on the stomach, and features of the underlying cause: fever, night sweats, and weight loss suggesting infection or lymphoma; lymphadenopathy suggesting lymphoproliferative disease; jaundice, ascites, and stigmata of chronic liver disease suggesting cirrhosis with congestive splenomegaly; pallor and jaundice suggesting hemolysis; travel or exposure history suggesting an infectious cause.

Careful abdominal palpation should distinguish the two organs (the spleen has a palpable notch, moves inferomedially with inspiration, and is not ballotable, while the liver edge is generally smoother and continuous with the costal margin) and estimate the degree of enlargement, since massive splenomegaly narrows the differential considerably toward chronic myeloid leukemia, myelofibrosis, or visceral leishmaniasis.

Abdominal ultrasound confirms organ size and assesses liver texture, portal vein diameter, and any focal lesions.

FBC with differential and blood film is essential, looking for cytopenias, blasts, atypical lymphocytes, or hemolysis markers.

LFTs and coagulation profile assess hepatic synthetic function. Further workup is directed by the leading clinical suspicion: malaria film or rapid diagnostic test, leishmania serology or bone marrow aspirate in endemic exposure, monospot or EBV serology, viral hepatitis serology, autoimmune and viral screen for cirrhosis workup, LDH and haptoglobin for hemolysis, and bone marrow aspirate and trephine biopsy with cytogenetics if a hematological malignancy is suspected on blood film or cytopenia pattern.

CT chest, abdomen, and pelvis assesses for lymphadenopathy and staging if lymphoma is suspected.

Differentials are extensive and are detailed individually in the Cirrhosis, Leukemia, Malaria, and Hemolytic conditions entries throughout this atlas, alongside the infectious and infiltrative causes above.

Management addresses the underlying cause identified through the workup above, as detailed in the relevant disease specific entries (Cirrhosis, Leukemia entries, Hodgkin and Non Hodgkin Lymphoma entries, Malaria, Leishmaniasis).

General supportive measures where splenomegaly itself causes significant symptoms or hypersplenism related cytopenia include monitoring for splenic rupture risk with activity modification advice in massive splenomegaly, and consideration of splenectomy in refractory hypersplenism or specific hematological indications, weighed against the long-term infection risk from functional asplenia (see Sickle Cell Disease entry for post-splenectomy vaccination and prophylaxis principles, which apply equally here).

Referral: hematology for unexplained hepatosplenomegaly with cytopenia or blood film abnormality; gastroenterology or hepatology if a chronic liver disease process is suspected; infectious disease for suspected visceral leishmaniasis, brucellosis, or other endemic infection.

Hepatitis E

Hepatitis E virus (HEV) is a non-enveloped RNA virus, predominantly transmitted via the fecal-oral route (contaminated water in endemic regions, genotypes 1 and 2), though genotype 3 (the dominant genotype in high income countries) is a zoonotic infection acquired from undercooked pork, wild boar, or deer products, and can also be transmitted via blood transfusion.

Usually causes a self-limiting acute hepatitis similar to hepatitis A, but with two important distinguishing features: markedly increased mortality in pregnant women (particularly third trimester, with fulminant hepatitis rates up to 20 to 25% and high maternal mortality), and the capacity to cause chronic infection in immunocompromised patients (notably solid organ transplant recipients), a pattern not seen with hepatitis A.

Similar to hepatitis A: prodromal malaise, nausea, and anorexia followed by jaundice, dark urine, and pale stools, generally self-limiting over several weeks in immunocompetent, non-pregnant individuals.

Pregnant women, particularly in the third trimester, are at markedly elevated risk of fulminant hepatic failure.

Immunocompromised patients (particularly transplant recipients on immunosuppression) may develop chronic HEV infection with persistent viremia, progressive fibrosis, and, in some cases, extrahepatic manifestations (notably a range of neurological syndromes including Guillain-Barré syndrome and neuralgic amyotrophy, increasingly recognized as HEV-associated).

Immunocompetent, non-pregnant patients: supportive care only, as for hepatitis A, with spontaneous resolution expected
Pregnancy: close monitoring given the significant fulminant hepatitis risk, with early involvement of hepatology and obstetric teams; management of established fulminant hepatic failure follows standard principles (see Acute Liver Failure entry), with delivery timing individualized
Chronic infection in immunocompromised patients: reduction of immunosuppression is the first step where feasible, which achieves clearance in a proportion of cases; ribavirin (typically for 3 months, monitored with HEV RNA) is used for persistent infection not clearing with immunosuppression reduction alone
Prevention: a hepatitis E vaccine is licensed and used in some endemic countries (notably China) but is not yet widely available globally; general prevention relies on safe water/sanitation in endemic settings and thorough cooking of pork products in genotype 3 endemic regions

Referral: hepatology for any immunocompromised patient (chronic infection management) or evidence of fulminant hepatitis; obstetrics for confirmed infection in pregnancy.

Hepatosplenomegaly

Overview

Clinical Features

Diagnosis

Management

Overview

Clinical Features

Diagnosis

Management